A new indicator of disease progression in gastrointestinal stromal tumors

Access through your institution Buy or subscribe Shankar S _et al_. (2005) Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib

mesylate. _Radiology_ 235: 892–898 Little is known about patterns of recurrence in gastrointestinal stromal tumors (GISTs) treated with the receptor tyrosine kinase inhibitor imatinib

mesylate (Gleevec® [previously Glivec®], Novartis, New York, NY). Shankar _et al_. have recently described an indicator of GIST disease progression that, to the knowledge of the authors, is

previously unreported: a new nodule within an existing mass. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe

to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF

Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact

customer support RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE A new indicator of disease progression in gastrointestinal stromal tumors. _Nat Rev Clin

Oncol_ 2, 330–331 (2005). https://doi.org/10.1038/ncponc0212 Download citation * Issue Date: July 2005 * DOI: https://doi.org/10.1038/ncponc0212 SHARE THIS ARTICLE Anyone you share the

following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer

Nature SharedIt content-sharing initiative